Allarity Therapeutics, Inc. announced that the Company concluded its Phase 2 clinical trial of stenoparib early due to clear clinical benefits observed, including tumor shrinkage and long-term disease stability, in heavily pre-treated ovarian cancer patients. Using the Company?s DRP® companion diagnostic to pre-screen patients, the trial targeted those most likely to benefit. The promising results have provided sufficient proof of concept, prompting the Company to halt enrollment with the purpose of preparing a follow-on trial with FDA regulatory intent.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4549 USD | -2.76% | -9.20% | -95.87% |
May. 24 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
May. 14 | Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-95.87% | 8.01M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ALLR Stock
- News Allarity Therapeutics, Inc.
- Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial